STARLITE-1: Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC (clinicaltrials.gov) - Oct 9, 2026 - P1/2 | N=100 | Suspended | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Suspended
Trial suspension • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|